Cargando…
Study of single nucleotide polymorphisms of FBW7 and its substrate genes revealed a predictive factor for paclitaxel plus cisplatin chemotherapy in Chinese patients with advanced esophageal squamous cell carcinoma
Paclitaxel plays a major role in the treatment of advanced esophageal squamous cell carcinoma. However, there is no biomarker that could be used to predict the clinical response of paclitaxel. This work was conducted to investigate the association of genetic polymorphisms in FBW7 and its substrate g...
Autores principales: | Liu, Ying, Xu, Shu Ning, Chen, Yong Shun, Wu, Xiao Yuan, Qiao, Lei, Li, Ke, Yuan, Long |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190100/ https://www.ncbi.nlm.nih.gov/pubmed/27259248 http://dx.doi.org/10.18632/oncotarget.9736 |
Ejemplares similares
-
Adjuvant chemotherapy with paclitaxel and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma
por: Zhang, Liangze, et al.
Publicado: (2017) -
Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma
por: Zhu, Han-Ting, et al.
Publicado: (2017) -
Chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma: A retrospective analysis
por: Yi, Qiong, et al.
Publicado: (2022) -
A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma
por: Wang, Hai-ying, et al.
Publicado: (2016) -
Fbw7 dimerization determines the specificity and robustness of substrate degradation
por: Welcker, Markus, et al.
Publicado: (2013)